News

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 May 2026.

Glaxosmithkline Pharmaceuticals announced that Vinay Subramanian, Commercial Head - Oncology would be part of leadership team effective 20 April 2026 based out of Mumbai, and he would be part of senior Management Personnel of the Company effective the said date. Vinay brings with him over 24 years of experience in the Pharmaceuticals, Life Science. Healthcare Devices, and Medical Technology sectors. Prior to joining GSK. he served as the India Enabling leader - Enterprise & Neighboring Countries at Roche Products India Pvt ltd. where he was responsible for the immunotherapy portfolio and was part of their leadership team.

Net profit of Glaxosmithkline Pharmaceuticals rose 28.60% to Rs 295.62 crore in the quarter ended December 2025 as against Rs 229.88 crore during the previous quarter ended December 2024. Sales rose 9.67% to Rs 1041.26 crore in the quarter ended December 2025 as against Rs 949.42 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1041.26949.42 10 OPM %35.6630.75 - PBDT402.27326.90 23 PBT381.95308.10 24 NP295.62229.88 29 Powered by Capital Market - Live News

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live News

Net profit of Glaxosmithkline Pharmaceuticals rose 1.98% to Rs 257.49 crore in the quarter ended September 2025 as against Rs 252.50 crore during the previous quarter ended September 2024. Sales declined 3.05% to Rs 979.94 crore in the quarter ended September 2025 as against Rs 1010.77 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales979.941010.77 -3 OPM %34.2631.83 - PBDT368.79355.98 4 PBT351.36339.12 4 NP257.49252.50 2 Powered by Capital Market - Live News